文献速递乳腺癌支持与姑息治疗

老年乳腺癌幸存者C反应蛋白升高与后续患者报告认知问题:思考与生活与癌症研究

Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
PubMed 文献 · J Clin Oncol · 2022-09-30

该纵向研究纳入400例新诊断老年乳腺癌幸存者和329例频率匹配对照,评估C反应蛋白(CRP)与认知的关系。幸存者在基线及12、24、60个月时调整后平均自然对数CRP显著高于对照(均P<.05)。幸存者中较高的调整后自然对数CRP预测后续访视时患者报告认知更差(交互P=.008),抑郁或焦虑不影响该结果。

要点

  • 老年乳腺癌幸存者基线及12、24、60个月调整后平均自然对数CRP显著高于非癌对照(均P<.05)。
  • 幸存者中较高调整后自然对数CRP预测后续患者报告认知更差,对照中无此关联(交互P=.008)。
  • CRP为3.0和10.0 mg/L时,幸存者调整后FACT-Cog评分分别比对照低9.5和14.2分。

核心结论

  • 老年乳腺癌幸存者中CRP与认知的纵向关系提示慢性炎症可能在认知问题发生中起作用,CRP检测在幸存者照护中可能具有临床用途。

研究设计与样本

  • 研究纳入年龄≥60岁、新诊断原发乳腺癌(0-III期)的英语女性及频率匹配对照,2010年9月至2020年3月入组,排除痴呆、神经系统疾病及其他癌症者。
  • 评估在系统治疗前/入组时及每年访视至60个月进行,认知用癌症治疗功能评估-认知功能(FACT-Cog)和神经心理测试测量。
  • 采用混合线性效应模型检验每次访视时幸存者与对照间自然对数转换CRP的差异,随机效应滞后波动模型检验自然对数CRP对后续认知的方向性效应。
  • 所有模型控制年龄、种族、研究站点、认知储备、肥胖和合并症,次要分析评估抑郁或焦虑是否影响结果。
  • 共有400例幸存者和329例对照有CRP标本和随访数据,平均年龄67.7岁(范围60-90岁),多数幸存者为I期(60.9%)、雌激素受体阳性(87.6%)肿瘤。

主要发现

  • 幸存者在基线及12、24、60个月访视时调整后平均自然对数CRP显著高于对照(均P<.05)。
  • 幸存者中较高调整后自然对数CRP预测后续访视时患者报告认知更差,对照中无此关联(交互P=.008),抑郁或焦虑不影响该效应。
  • CRP水平为3.0和10.0 mg/L时,幸存者调整后FACT-Cog评分分别比对照低9.5和14.2分。
  • 幸存者神经心理测试表现较对照差,仅Trails B测试与CRP存在显著交互。

临床怎么用

  • 原文结论指出CRP检测在幸存者照护中可能具有临床用途。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls. METHODS: English-speaking women age ≥ 60 years, newly diagnosed with primary breast cancer (stage 0-III), and frequency-matched controls were enrolled from September 2010 to March 2020; women with dementia, neurologic disorders, and other cancers were excluded. Assessments occurred presystemic therapy/enrollment and at annual visits up to 60 months. Cognition was measured using the Functional Assessment of Cancer Therapy-Cognitive Function and neuropsychological testing. Mixed linear effect models tested for survivor-control differences in natural log (ln)-transformed CRP at each visit. Random effect-lagged fluctuation models tested directional effects of ln-CRP on subsequent cognition. All models controlled for age, race, study site, cognitive reserve, obesity, and comorbidities; secondary analyses evaluated if depression or anxiety affected results. RESULTS: There were 400 survivors and 329 controls with CRP specimens and follow-up data (average age of 67.7 years; range, 60-90 years). The majority of survivors had stage I (60.9%), estrogen receptor-positive (87.6%) tumors. Survivors had significantly higher adjusted mean ln-CRP than controls at baseline and 12-, 24-, and 60-month visits (all P < .05). Higher adjusted ln-CRP predicted lower participant-reported cognition on subsequent visits among survivors, but not controls (P interaction = .008); effects were unchanged by depression or anxiety. Overall, survivors had adjusted Functional Assessment of Cancer Therapy-Cognitive Function scores that were 9.5 and 14.2 points lower than controls at CRP levels of 3.0 and 10.0 mg/L. Survivors had poorer neuropsychological test performance (v controls), with significant interactions with CRP only for the Trails B test. CONCLUSION: Longitudinal relationships between CRP and cognition in older breast cancer survivors suggest that chronic inflammation may play a role in development of cognitive problems. CRP testing could be clinically useful in survivorship care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Carroll JE, Nakamura ZM, Small BJ, et al. Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. J Clin Oncol. 2022. PMID: 36179271. doi:10.1200/JCO.22.00406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。